Maxim Group Maintains Buy on NeuroOne Medical Tech, Lowers Price Target to $5
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Maxim Group analyst Anthony Vendetti maintains NeuroOne Medical Tech (NASDAQ:NMTC) with a Buy and lowers the price target from $13 to $5.
Maxim Group analyst Anthony Vendetti maintains NeuroOne Medical Tech (NASDAQ:NMTC) with a Buy and lowers the price target from $13 to $5.